Weekly epirubicin in patients with hormone refractory prostatic cancer--a two-year follow-up
Burk, K.; Schultze-Seemann, W.; Jonas, D.; Rodeck, G.
Progress in Clinical and Biological Research 303: 277-285
1989
ISSN/ISBN: 0361-7742 PMID: 2674990 Document Number: 328099
Document emailed within 1 workday
Related Documents
Weissbach, L. 1992: Prospective randomized multicenter phase IIi study of treatment of hormone refractory prostatic cancer: mitomycin C vs. 4-epirubicin vs. estramustine phosphate Der Urologe. Ausg. a 31(1): 62Coccaro, M.; Tartarone, A.; Romano, G.; Ardito, R.; Di Renzo, N. 2005: Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer Tumori 91(4): 314-316
Stoter, G.; Jones, W.G. 1988: Chemotherapy of hormone refractory prostatic cancer Progress in Clinical and Biological Research 260: 123-125
Barni, S.; Archili, C.; Lissoni, P.; Paolorossi, F.; Crispino, S.; Tancini, G. 1993: A weekly schedule of epirubicin in pretreated advanced breast cancer Tumori 79(1): 45-48
Chang, A.Y.; Boros, L.; Asbury, R.; Hui, L.; Rubins, J. 1997: Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer Seminars in Oncology 24(5 Suppl 17: S17
Ngo, L.S.M.; Yeo, A.; Wong, A.S.C.; Tay, M.Hiang. 2007: Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Annals of the Academy of Medicine Singapore 36(10): 811-814
Saimura, M.; Mitsuyama, S.; Anan, K.; Tanaka, M.; Shimada, K.; Hirose, N.; Ogawa, S.; Tamaki, N.; Tomisaki, S.; Tamura, K. 2008: Adjuvant epirubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(9): 1519-1523
Pummer, K. 1991: Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer Seminars in Oncology 18(5 Suppl 6: 26-28
Bigazzi, R.; Gentini, G.P.; Mazzoni, A.; Setti, G.P.; Cocciolo, G.; Ghiara, F.; Silvis, C.; Baldari, G. 1984: Hemodiafiltration (HD-HF): one year follow-up of nine hours weekly International Journal of Artificial Organs 7(4): 189-192
Aćimović, M.; Rafailović, D.; Bumbaširević, U.š; Babić, U.š; Šantrić, V.; Stanić, M.; Džamić, Z.; Hadži-Djokić, J. 2014: Diode laser vaporization of prostate as treatment for benign prostatic enlargement: initial results of 73 patients with 1 year follow-up Acta Chirurgica Iugoslavica 61(1): 21-24
Fujinami, K.; Miura, T.; Takizawa, A.; Osada, Y. 2005: Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 51(1): 5-8
Kimura, M.; Sano, M.; Tabei, T.; Asaga, T.; Ando, J.; Fujii, H.; Yamamoto, N.; Kurosumi, M. 2005: Study of three-weekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(3): 335-339
Awakura, Y.; Yamamoto, M.; Fukuzawa, S.; Itoh, N.; Nonomura, M.; Fukuyama, T. 2000: Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 46(7): 449-452
Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. 2003: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer Research 23(2c): 1951-1954
Kawaguchi, T.; Mayama, I.; Iwabuchi, I.; Ogasawara, M.; Tsukui, A. 2010: Chemo-endocrine therapy with low-dose cisplatin, UFT, and dexamethasone for hormone-refractory prostate cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(10): 1921-1925
Miglietta, L.; Cannobbio, L.; Boccardo, F. 1995: Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity Anticancer Research 15(6b): 2825-2828
Koyama, H.; Iesato, A.; Fukushima, Y.; Okada, T.; Watanabe, T.; Harada, M.; Ito, T.; Maeno, K.; Mochizuki, Y.; Ito, K.; Amano, J. 2011: A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1123-1126
Palacio, A.; Hernández, C.; Marqués, A.; Prats, J.; Espinosa, F.J. 2004: Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report Archivos Espanoles de Urologia 57(4): 451-460
Oishi, K.; Arai, Y.; Takeuchi, H.; Yoshida, O. 1993: Side effects of estrogen administration to prostatic cancer patients: clinical and statistical survey of 109 prostatic cancer cases of Kyoto University Hospital Hinyokika Kiyo. Acta Urologica Japonica 39(1): 23-28
De Voogt, H.J.; Adenauer, H.; Widdra, W.G. 1991: The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. a 10-year review on 1522 patients treated in 119 centres on 4 continents Scandinavian Journal of Urology and Nephrology. Supplementum 138: 131-136